MedTrace Logo

Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC

NCT06508229 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2024-07-18

No results posted yet for this study

Summary

This is a multi-center, single-arm, phase II clinical study designed to observe and evaluate the effectiveness and safety of adebrelimab combined with albumin paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced resectable esophageal squamous cell carcinoma.

Conditions

Interventions

DRUG

Adebrelimab

adebrelimab, IV

DRUG

albumin paclitaxel

albumin paclitaxel, iv

DRUG

Nedaplatin

Nedaplatin，IV

Sponsors & Collaborators

  • Harbin Medical University

    lead OTHER

Principal Investigators

  • Jianqun Ma, MD · Harbin Medical University Affiliated Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-30
Primary Completion
2027-05-30
Completion
2028-05-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06508229 on ClinicalTrials.gov